Key result
Sacubitril/valsartan review outlines its development, prior drug failures, and ongoing trials for new HF indications.
This review summarizes the development and FDA approval of sacubitril/valsartan for the management of heart failure with reduced ejection fraction.
Answers are grounded in this paper and cite their sources.
Provides context for sacubitril/valsartan in approved HFrEF use; leaves open expansion to new indications pending randomized data.
Heart Failure (HF) is one of the main healthcare burdens in the United States and in the world. Many drugs are approved and used in practice for management of this condition; including beta blockers, diuretics, aldosterone antagonists, Angiotensin Converting Enzyme Inhibitors (ACEI’s), and Angiotensin Receptor Blockers (ARBs). Recently, the Food and Drug Administration (FDA) approved a drug with brand name Entresto (Sacubitril/Valsartan or LCZ696), an angiotensin receptor neprilysin inhibitor for the use in Heart Failure with Reduced Ejection Fraction (HFrEF) patients instead of ACEI’s and ARBs. The drug works through angiotensin receptor blockage via valsartan as well as neprilysin inhibition with sacubitril. This represented a new milestone in managing heart failure patients and provided yet another therapy in our armamentarium. This article reviews the stages that led to the development of this drug, the failure of its preceding agents, the lessons we have learnt, and the current trials of Entresto for new indications.
No takes yet. Share an insight, caveat, or question.
Khalil et al. (2018) conducted a review in Heart Failure with Reduced Ejection Fraction (HFrEF). Entresto (Sacubitril/Valsartan) was evaluated. This review summarizes the development of sacubitril/valsartan, the failure of preceding agents, and current trials for new indications in heart failure management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: